The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•13 February 2026•

1 min read

Merck Receives FDA Approval for KEYTRUDA in Ovarian Cancer Treatment

FDA and Novo Nordisk logos above a laboratory scene with computer monitors, chemical structures, medicine bottles, and pills.

Merck & Co. (MRK) announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA and KEYTRUDA QLEX in combination with paclitaxel for specific types of ovarian cancer. This approval targets adult patients with PD-L1+ platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma. Notably, this marks the first and only PD-1 inhibitor approved for this specific patient population, addressing a significant unmet medical need. The regulatory decision was supported by results from the Phase 3 KEYNOTE-B96 trial, which demonstrated a significant reduction in the risk of disease progression or death. This milestone is expected to strengthen Merck's oncology portfolio and enhance the long-term revenue outlook for its flagship drug. Investors and analysts view this development as a positive driver for the company's market position in the competitive pharmaceutical sector.